Aeglea Biotherapeutics Inc. (AGLE) Rating Reiterated by BMO Capital Markets
Aeglea Biotherapeutics Inc. (NASDAQ:AGLE)‘s stock had its “buy” rating restated by analysts at BMO Capital Markets in a research report issued on Thursday. They presently have a $19.00 target price on the stock. BMO Capital Markets’ price target indicates a potential upside of 220.40% from the company’s previous close.
Separately, Zacks Investment Research upgraded Aeglea Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 13th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 5.93 on Thursday. Aeglea Biotherapeutics has a one year low of $3.89 and a one year high of $12.75. The firm’s 50-day moving average price is $6.36 and its 200 day moving average price is $6.23. The stock’s market cap is $79.64 million.
Large investors have recently bought and sold shares of the company. University of Texas Investment Managment Co. acquired a new stake in Aeglea Biotherapeutics during the third quarter valued at about $3,365,000. Jennison Associates LLC boosted its position in shares of Aeglea Biotherapeutics by 2.7% in the third quarter. Jennison Associates LLC now owns 1,424,947 shares of the company’s stock worth $9,131,000 after buying an additional 36,868 shares during the last quarter. VHCP Management II LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $1,527,000. Ghost Tree Capital LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $243,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $515,000. Institutional investors and hedge funds own 44.94% of the company’s stock.
Aeglea Biotherapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Stock Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.